Product
SOK583A1
Aliases
SOK583A1 (40 mg/mL)
3 clinical trials
2 indications
Indication
Age-Related Macular DegenerationClinical trial
A 52-week Multicenter, Randomized, Double-masked, 2-arm Parallel Study to Compare Efficacy, Safety and Immunogenicity of SOK583A1 to Eylea®, Administered Intravitreally, in Patients With Neovascular Age-related Macular DegenerationStatus: Completed, Estimated PCD: 2022-07-07
Clinical trial
An Open-label, Single-arm, Multicenter Study in Patients With Neovascular Age-related Macular Degeneration to Evaluate the Safety of SOK583A1 (40 mg/mL), a Proposed Aflibercept Biosimilar Product, Provided in a Prefilled SyringeStatus: Completed, Estimated PCD: 2022-05-04
Clinical trial
An Open-label, Single-arm, Multicenter Study in Patients With Neovascular Age-related Macular Degeneration to Evaluate the Safety of SOK583A1 (40 mg/mL), a Proposed Aflibercept Biosimilar Product, Provided in a Vial KitStatus: Completed, Estimated PCD: 2022-09-07